Stockreport

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipelineCash runway extended into the second quarter of 2028 CRANBURY, N.J.-- [Read more]